WHAT IS CLAIMED IS:

1. A compound having a formula I,



I

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

A_1 is: a bond, CH_2, O or S, and wherein A_1 and R^4 or A_1 and R^5 together being a 3- to 6-membered carbocyclyl when A_1 is a carbon;

A_2 and A_3 are independently: CH_2, O or S;

E_1, E_2, E_3, E_4 and E_5 are each CH or substituted carbon bearing A_2 and R^3; or at least one of E_1, E_2, E_3, E_4 and E_5 is nitrogen and each of others being CH or substituted carbon bearing A_2 and R^3;

Q is: $-C(O)OR^6$, or R^{6A};

Y is: a bond, C_1-C_6 alkyl or C_3-C_6 cycloalkyl;

Z is:
a) aryl;
b) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,
c) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl, or
d) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and wherein aryl, heteroaryl, bi-aryl and bi-heteroaryl being optionally substituted with one or more groups independently selected from R^7;

n is: 1, 2, 3, 4, 5 or 6

p is: 1 or 2;

r is: 1, 2, 3, or 4;

R^1 and R^2 are each independently:

hydrogen,

haloalkyl,

C_1-C_6 alkyl,

$(CH_2)_nC_3$-C_8 cycloalkyl, or

R^1 and R^2 form a 4- to 8-membered nonaromatic carbocyclic ring; and wherein at least one of R^1 and R^2 is alkyl or cycloalkyl, and;

R^3 is: hydrogen,

nitro,

cyano,

hydroxyl,

halo,

haloalkyl,

haloalkyloxy,

aryloxy,

C_1-C_6 alkyl,

C_1-C_6 alkoxy, or

C_3-C_8 cycloalkyl;

R^4 and R^5 are each independently: hydrogen or C_1-C_6 alkyl;

R^6 is: hydrogen, C_1-C_6 alkyl or aminoalkyl;

R^{6A} is: carboxamide, sulfonamide, acylsulfonamide, tetrazole,



or

;

R^7 is: hydrogen,
oxo,
nitro,
cyano,
hydroxyl,
halo,
haloalkyl,
haloalkyloxy,
aryloxy,
arylalkyl,
aminoalkyl,
C_1-C_6 alkyl,
C_1-C_6 alkoxy,
$(CH_2)_nC_3$-C_8 cycloalkyl,
$C(O)R^9$,
$C(O)OR^9$,
$C(=NOR^8)R^9$,
$CR^8(OH)R^9$,
$C[=C(R^8)_2]R^9$,
OR^9,
SR^9 or

$S(O)_pR^9$;

R^8 is: hydrogen or C_1-C_6 alkyl; and

R^9 is: hydrogen,
C_1-C_6 alkyl,
C_3-C_8 cycloalkyl,
aryl,
heteroaryl or
heterocyclyl,
wherein alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of:
hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C_1-C_6 alkyl, C_1-C_6 alkoxy and C_3-C_8 cycloalkyl.

2. The compound of Claim 1, wherein the compound having a formula II,



II

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

A_1 is: a bond, CH_2, O or S, and wherein A_1 and R^4 or A_1 and R^5 together being a 3- to 6-membered carbocyclyl when A_1 is a carbon;

A_2 is: O or S or CH_2;

Q is: $-C(O)OR^6$, or R^{6A};

Y is: a bond, C_1-C_6 alkyl or C_3-C_6 cycloalkyl;

Z is: a) aryl;

b) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,

c) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl, or

d) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and

wherein aryl, heteroaryl, bi-aryl and bi-heteroaryl being optionally substituted with one or more groups independently selected from R^7;

n is: 1, 2, 3, 4, 5 or 6

p is: 1 or 2;

r is: 1, 2, 3, or 4;

R^1 and R^2 are each independently:

hydrogen,

haloalkyl,

C_1-C_6 alkyl,

$(CH_2)_nC_3$-C_8 cycloalkyl, or

R^1 and R^2 form a 4- to 8-membered nonaromatic carbocyclic ring; and

wherein at least one of R^1 and R^2 is alkyl or cycloalkyl, and;

R^3 is: hydrogen,

nitro,

cyano,

hydroxyl,

halo,

haloalkyl,

haloalkyloxy,

aryloxy,

C_1-C_6 alkyl,

C_1-C_6 alkoxy, or

C_3-C_8 cycloalkyl;

R^4 and R^5 are each independently: hydrogen or C_1-C_6 alkyl;

R^6 is: hydrogen, C_1-C_6 alkyl or aminoalkyl;

R^{6A} is: carboxamide, sulfonamide, acylsulfonamide, tetrazole,



;

R^7 is: hydrogen,
oxo,
nitro,
cyano,
hydroxyl,
halo,
haloalkyl,
haloalkyloxy,
aryloxy,
arylalkyl,
aminoalkyl,
C_1-C_6 alkyl,
C_1-C_6 alkoxy,
$(CH_2)_nC_3$-C_8 cycloalkyl,
$C(O)R^9$,
$C(O)OR^9$,
$C(=NOR^8)R^9$,

$CR^8(OH)R^9$,
$C[=C(R^8)_2]R^9$,
OR^9,
SR^9 or
$S(O)_pR^9$;

R^8 is: hydrogen or C_1-C_6 alkyl; and

R^9 is: hydrogen,
C_1-C_6 alkyl,
C_3-C_8 cycloalkyl,
aryl,
heteroaryl or
heterocyclyl,
wherein alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of:
hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C_1-C_6 alkyl, C_1-C_6 alkoxy and C_3-C_8 cycloalkyl.

3. The compound of Claim 2, wherein Z is optionally substituted phenyl or naphthyl, furanyl, imidazolyl, indolyl, oxazolyl, isoxazolyl, pyridyl, pyrrolyl, thiazolyl, thiophenyl, benzofuranyl, benzothiophenyl, benzoisoxazolyl, quinolinyl, isoquinolinyl or a structural formula selected from following:



wherein T is:

a bond, $-(CH_2)_qO-$, $-O(CH_2)_q-$, $-C(O)(CH_2)_q-$, $-(CH_2)_qC(O)-$, $-(CH_2)_qS-$, $-S(CH_2)_q-$, $S[O]_p$, $-(C_1-C_3$ alkyl)-, $-(CH_2)_qC(=CH_2)-$, $-C(=CH_2)(CH_2)_q-$, $-(CH_2)_qC(=NOH)-$, $-C(=NOH)(CH_2)_q-$, $-(CH_2)_qC(=NOCH_3)-$, $-C(=NOCH_3)(CH_2)_q-$, $-CH(OH)(CH_2)_q-$, or $-(CH_2)_qCH(OH)-$,

q is: 0, 1, 2 or 3; and

rings b to l are each optionally substituted with one or more groups independently selected from the group consisting of:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$, C_1-C_6 alkyl, C_1-C_6 alkoxy and $(CH_2)_nC_3-C_8$ cycloalkyl.

4. The compound of Claim 2, wherein the compound having a structural formula III,



III

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein m is 1, 2, 3 or 4.

5. The compound of Claim 4, wherein the compound having a structural formula IV,



IV

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

A_1 and A_2 are respectively:

O and O,

CH_2 and O,

CH_2 and S,

O and S or

S and O;

m is: 1 or 2;

R^1 is: C_1-C_3 alkyl;

R^3 is: hydrogen, halo or C_1-C_6 alkyl;

R^6 and R^9 are each independently: hydrogen or C_1-C_6 alkyl;

T is: a bond, -O-, -C(O)-, -S(O) $-S(O)_2$-, $-C(=CH_2)$-, -C(=NOH)- or -CH(OH)-; and

rings b and c are each optionally substituted with one or more groups independently selected from:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$, C_1-C_6 alkyl, C_1-C_6 alkoxy and $(CH_2)_nC_3$-C_8 cycloalkyl.

6. The compound of Claim 5, wherein the compound having a structural formula V,



V

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

T is: a bond, -O- or -C(O)-;

R^1 is: methyl, ethyl or cyclopropyl;

R^3 is: methyl or ethyl; and

rings b and c are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF_3, OCF_3, methyl, ethyl, isopropyl, $N(CH_3)_2$, $S(O)_2CH_3$, methoxy and cyclopropyl.

7. The compound of Claim 6, wherein the compound is represented by a structural formula VI,



VI

or a pharmaceutically acceptable salt, solvate or hydrate thereof.

8. The compound of Claim 2, wherein the compound having a structural formula VII,



VII

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

Z is:



or

A_1 and A_2 are respectively: bond and S; bond and O; CH_2 and S; or CH_2 and O;

m is: 1 or 2;

R^1 is: C_1-C_3 alkyl;

R^3 is: hydrogen, halo or C_1-C_6 alkyl;

R^6 and R^9 are each independently: hydrogen or C_1-C_6 alkyl;

T is: bond, -O-, -C(O)-, -S(O) –$S(O)_2$-, -C(=CH_2)-, -C(=NOH)- or -CH(OH)-; and rings b, c, k and l are each optionally substituted with one or more groups independently selected from:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$, C_1-C_6 alkyl, C_1-C_6 alkoxy and $(CH_2)_nC_3$-C_8 cycloalkyl.

9. The compound of Claim 8, wherein R^1 is: methyl, ethyl or cyclopropyl; R^3 is: methyl or ethyl; and rings b, c k and l are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF_3, OCF_3, $N(CH_3)_2$, $S(O)_2CH_3$, methyl, ethyl, isopropyl, methoxy and cyclopropyl.

10. The compound of Claim 4, wherein the compound having a structural formula VIII,



VIII

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

A_1 and A_2 are respectively:

O and O,

CH_2 and O,

CH_2 and S,

O and S or

S and O;

m is: 1 or 2;

R^1 is: C_1-C_3 alkyl; and

R^3 is: hydrogen, halo or C_1-C_6 alkyl;

R^6 and $R^9$are each independently: hydrogen or C_1-C_6 alkyl;

T is: a bond, -O-, -C(O)-, -S(O) –$S(O)_2$-, -C(=CH_2)-, -C(=NOH)- or -CH(OH)-; and

ring b is optionally substituted with one or more groups independently selected from: hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$, C_1-C_6 alkyl, C_1-C_6 alkoxy and $(CH_2)_nC_3$-C_8 cycloalkyl.

11. The compound of Claim 10, wherein the compound having a structural formula IX,



IX

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

R^1 is C_1-C_3 alkyl;

R^3 is: hydrogen, halo or C_1-C_4 alkyl;

ring b is optionally substituted with one or more groups independently selected from the group consisting of: hydrogen, halo, haloalkyl, haloalkyloxy and C_1-C_6 alkyl.

12. The compound of Claim 11, wherein the compound having a structural formula X,



X

or a pharmaceutically acceptable salt, solvate or hydrate thereof.

13. The compound of Claim 11, wherein the compound having a structural formula XI,



XI

or a pharmaceutically acceptable salt, solvate or hydrate thereof.

14. The compound of Claim 4, wherein the compound having a structural formula XII,



XII

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

A_1 and A_2 are respectively:

O and O,

CH_2 and O,

CH_2 and S,

O and S or

S and O;

m is: 1 or 2;

R^1 is: C_1-C_3 alkyl; and

R^3 is: hydrogen, halo or C_1-C_6 alkyl;

R^4, R^5, R^6 and R^9 are each independently: hydrogen or C_1-C_6 alkyl;

rings k and l are each optionally substituted with one or more groups independently selected from:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$, C_1-C_6 alkyl, C_1-C_6 alkoxy and $(CH_2)_nC_3$-C_8 cycloalkyl.

15. The compound of Claim 14, wherein R^4 and R^5 are each methyl or ethyl; m is 1; rings k and l are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF_3, OCF_3, $N(CH_3)_2$, $S(O)_2CH_3$, methyl, ethyl, isopropyl, methoxy and cyclopropyl; and oxygen atom of -O-CH(R^1)-$(CH_2)_m$- moiety is placed in an ortho position relative to the ring l.

16. The compound of Claim 2, wherein the compound having a structural formula XIII,



XIII

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein m is 1, 2, 3, or 4.

17. The compound of Claim 16, wherein the compound having a structural formula XIV,



XIV

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

A_1 and A_2 are respectively:

O and O,

CH_2 and O,

CH_2 and S,

O and S, or

S and O;

m is: 1 or 2;

R^2 is: C_1-C_3 alkyl; and

R^3 is: hydrogen, halo or C_1-C_6 alkyl;

R^6 and R^9 are each independently: hydrogen or C_1-C_6 alkyl;

T is: a bond, -O-, -C(O)-, -S(O) –$S(O)_2$-, -C(=CH_2)-, -C(=NOH)- or -CH(OH)-; and

rings b and c are each optionally substituted with one or more groups independently selected from:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$, C_1-C_6 alkyl, C_1-C_6 alkoxy and $(CH_2)_nC_3$-C_8 cycloalkyl.

18. The compound of Claim 17, wherein the compound having a structural formula XV,



XV

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

T is: a bond, O or C(O);

R^2 is: methyl, ethyl or cyclopropyl;

R^3 is: methyl or ethyl; and

rings b and c are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF_3, OCF_3, $N(CH_3)_2$, $S(O)_2CH_3$, methyl, ethyl, isopropyl, methoxy and cyclopropyl.

19. The compound of Claim 2, wherein the compound having a structural formula XVI,



XVI

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein Y is a branched alkyl or C_3-C_6 cycloalkyl.

20. The compound of Claim 19, wherein the compound having a structural formula XVII,



XVII

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:
A_1 and A_2 are respectively:

O and O,

CH_2 and O,

CH_2 and S,

O and S, or

S and O;

R^3 is: hydrogen, halo or C_1-C_6 alkyl;

R^6 and R^9 are each independently: hydrogen or C_1-C_6 alkyl;

R^{9a} and R^{9b} are:

each independently hydrogen or C_1-C_4 alkyl wherein at least one of R^{9a} and R^{9b} being C_1-C_4 alkyl, or together C_3-C_6 cycloalkyl;

T is: a bond, -O-, -C(O)-, -S(O) –$S(O)_2$-, -C(=CH_2)-, -C(=NOH)- or -CH(OH)-; and

rings b and c are each optionally substituted with one or more groups independently selected from:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$, C_1-C_6 alkyl, C_1-C_6 alkoxy and $(CH_2)_nC_3$-C_8 cycloalkyl.

21. The compound of Claim 20, wherein the compound having a structural formula XVIII,



XVIII

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

T is: a bond, O or C(O);

R^3 is: methyl or ethyl;

R^{9a} and R^{9b} are each independently hydrogen, methyl or ethyl, wherein at least one of R^{9a} and R^{9b} being methyl or ethyl;

rings b and c are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF_3, OCF_3, $S(O)_2CH_3$, $N(CH_3)_2$, methyl, ethyl, isopropyl, methoxy and cyclopropyl.

22. The compound of Claim 21, wherein the compound having a structural formula XIX,



XIX

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof.

23. The compound of Claim 1, wherein the compound having a formula XX,



XX

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

A_1 is: a bond, CH_2, O or S, and wherein A_1 and R^4 or A_1 and R^5 together being a 3- to 6-membered carbocyclyl when A_1 is a carbon;

A_2 is: O or S or CH_2;

Q is: $-C(O)OR^6$, or R^{6A};

Y is: a bond, C_1-C_6 alkyl or C_3-C_6 cycloalkyl;

Z is: a) aryl;

b) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,

c) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl, or

d) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and

wherein aryl, heteroaryl, bi-aryl and bi-heteroaryl being optionally substituted with one or more groups independently selected from R^7;

n is: 1, 2, 3, 4, 5 or 6

p is: 1 or 2;

r is: 1, 2, 3, or 4;

R^1 and R^2 are each independently:

hydrogen,

haloalkyl,

C_1-C_6 alkyl,

$(CH_2)_nC_3$-C_8 cycloalkyl, or

R^1 and R^2 form a 4- to 8-membered nonaromatic carbocyclic ring; and wherein at least one of R^1 and R^2 is alkyl or cycloalkyl, and;

R^3 is: hydrogen,

nitro,

cyano,

hydroxyl,

halo,

haloalkyl,

haloalkyloxy,

aryloxy,

C_1-C_6 alkyl,

C_1-C_6 alkoxy, or

C_3-C_8 cycloalkyl;

R^4 and R^5 are each independently: hydrogen or C_1-C_6 alkyl;

R^6 is: hydrogen, C_1-C_6 alkyl or aminoalkyl;

R^{6A} is: carboxamide, sulfonamide, acylsulfonamide, tetrazole,



or

;

R^7 is: hydrogen,
oxo,
nitro,
cyano,
hydroxyl,
halo,
haloalkyl,
haloalkyloxy,
aryloxy,
arylalkyl,
aminoalkyl,
C_1-C_6 alkyl,
C_1-C_6 alkoxy,
$(CH_2)_nC_3$-C_8 cycloalkyl,
$C(O)R^9$,
$C(O)OR^9$,
$C(=NOR^8)R^9$,

$CR^8(OH)R^9$,
$C[=C(R^8)_2]R^9$,
OR^9,
SR^9 or
$S(O)_pR^9$;

R^8 is: hydrogen or C_1-C_6 alkyl; and

R^9 is: hydrogen,
C_1-C_6 alkyl,
C_3-C_8 cycloalkyl,
aryl,
heteroaryl or
heterocyclyl,
wherein alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of:
hydrogen, [illegible] haloalkyl, haloalkyloxy, aryloxy,
oxo, C_1-C_6 [illegible] C_1-C_6 alkoxy and C_3-C_8 cycloalkyl.

24. The compound of Claim 23, wherein Z is optionally substituted phenyl or naphthyl, furanyl, imidazolyl, indolyl, oxazolyl, isoxazolyl, pyridyl, pyrrolyl, thiazolyl, thiophenyl, benzofuranyl, benzothiophenyl, benzoisoxazolyl, quinolinyl, isoquinolinyl or a structural formula selected from following:



wherein T is:

a bond, $-(CH_2)_qO-$, $-O(CH_2)_q-$, $-C(O)(CH_2)_q-$, $-(CH_2)_qC(O)-$, $-(CH_2)_qS-$, $-S(CH_2)_q-$, $S[O]_p$, $-(C_1-C_3$ alkyl)-, $-(CH_2)_qC(=CH_2)-$, $-C(=CH_2)(CH_2)_q-$, $-(CH_2)_qC(=NOH)-$, $-C(=NOH)(CH_2)_q-$, $-(CH_2)_qC(=NOCH_3)-$, $-C(=NOCH_3)(CH_2)_q-$, $-CH(OH)(CH_2)_q-$, or $-(CH_2)_qCH(OH)-$,

q is: 0, 1, 2 or 3; and

rings b to j are each optionally substituted with one or more groups independently selected from the group consisting of:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$, C_1-C_6 alkyl, C_1-C_6 alkoxy and $(CH_2)_nC_3-C_8$ cycloalkyl.

25. The compound of Claim 24, wherein the compound having a structural formula XXI,



XXI

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

A_1 and A_2 are respectively:

O and O,

CH_2 and O,

CH_2 and S,

O and S or

S and O;

m is: 1, 2, 3 or 4;

R^1 is: C_1-C_3 alkyl; and

R^3 is: hydrogen, halo or C_1-C_6 alkyl;

R^6 and R^9 are each independently: hydrogen or C_1-C_6 alkyl;

T is: a bond, -O-, -C(O)-, -S(O) $-S(O)_2$-, -C(=CH_2)-, -C(=NOH)- or -CH(OH)-; and

rings b and c are each optionally substituted with one or more groups independently selected from:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$, C_1-C_6 alkyl, C_1-C_6 alkoxy and $(CH_2)_nC_3$-C_8 cycloalkyl.

26. The compound of Claim 25, wherein the compound having a structural formula XXII,



XXII

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

T is: a bond, -O- or -C(O)-;

R^1 is: methyl, ethyl or cyclopropyl;

R^3 is: methyl or ethyl; and

rings b and c are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF_3, OCF_3, $S(O)_2CH_3$, $N(CH_3)_2$, methyl, ethyl, isopropyl, methoxy and cyclopropyl.

27. The compound of Claim 1, wherein the compound having a structural formula XXIII,



XXIII

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

A_1 and A_2 are respectively:

O and O,

CH_2 and O,

CH_2 and S,

O and S or

S and O;

m is: 1, 2, 3 or 4;

R^1 is: C_1-C_3 alkyl; and

R^3 is: hydrogen, halo or C_1-C_6 alkyl;

R^6 and R^9 are each independently: hydrogen or C_1-C_6 alkyl;

T is: a bond, -O-, -C(O)-, -S(O) –$S(O)_2$-, -C(=CH_2)-, -C(=NOH)- or -CH(OH)-; and

rings b and c are each optionally substituted with one or more groups independently selected from:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$, C_1-C_6 alkyl, C_1-C_6 alkoxy and $(CH_2)_nC_3$-C_8 cycloalkyl.

28. The compound of Claim 27, wherein the compound having a structural formula XXIV,



XXIV

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

T is: a bond, -O- or -C(O)-;

R^1 is: methyl, ethyl or cyclopropyl;

R^3 is: methyl or ethyl; and

rings b and c are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF_3, OCF_3, $S(O)_2CH_3$, $N(CH_3)_2$, methyl, ethyl, isopropyl, methoxy and cyclopropyl.

29. A compound selected from the group consisting of:

No.	Structure	Name
1		3-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
2		{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenoxy}-acetic acid
3		{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
4		{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
5		{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butylsulfanyl]-2-methyl-phenoxy}-acetic acid

No.	Structure	Name
6		3-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butylsulfanyl]-2-methyl-phenyl}-propionic acid
7		2-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenoxy}-2-methyl-propionic acid
8		{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-phenoxy}-acetic acid
9		3-{4-[3-(2-Benzoyl-4-isopropyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
10	Chiral 	3-{4-[3-(2-Benzoyl-4-cyclopropyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid

No.	Structure	Name
11		3-{4-[3-(2-Benzoyl-4-trifluoromethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
12		3-{4-[3-(2-Benzoyl-4-chloro-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
13		3-{4-[3-(2-Benzoyl-4-chloro-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
14	Chiral 	3-{4-[3-(2-Benzoyl-4-methoxy-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
15	Chiral 	3-{4-[3-(2-Benzoyl-4-fluoro-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid

No.	Structure	Name
16	Chiral 	3-{4-[3-(2-Benzoyl-4-isopropyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
17	Chiral 	{4-[3-(2-Benzoyl-4-isopropyl-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
18		{4-[3-(2-Benzoyl-4-chloro-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
19		3-(4-{3-[4-Ethyl-2-(hydroxy-phenyl-methyl)-phenoxy]-butoxy}-2-methyl-phenyl)-propionic acid
20		3-(4-{3-[4-Ethyl-2-(hydroxyimino-phenyl-methyl)-phenoxy]-butoxy}-2-methyl-phenyl)-propionic acid

No.	Structure	Name
21		3-(4-{3-[4-Ethyl-2-(methoxyimino-phenyl-methyl)-phenoxy]-butoxy}-2-methyl-phenyl)-propionic acid
22	 Chiral	3-{4-[3-(4-Isopropyl-2-phenoxy-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
23	 Chiral	{4-[3-(4-Isopropyl-2-phenoxy-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
24		3-{4-[3-(4-Ethyl-2-isobutyryl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
25		3-{4-[3-(2-Cyclopropanecarbonyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid

No.	Structure	Name
26		3-{4-[3-(2-Cyclopropanecarbonyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
27		3-{4-[3-(2-Cyclopentanecarbonyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
28		2-{4-[3-(4-Ethyl-2-isobutyryl-phenoxy)-butoxy]-phenoxy}-2-methyl-propionic acid
29		2-{4-[3-(2-Cyclopropanecarbonyl-4-ethyl-phenoxy)-butoxy]-phenoxy}-2-methyl-propionic acid
30		3-{4-[3-(3-Benzoyl-5-ethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
31		{4-[3-(3-Benzoyl-5-ethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid

No.	Structure	Name
32	Chiral 	3-{4-[3-(3-Benzoyl-5-chloro-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
33	Chiral 	{4-[3-(3-Benzoyl-5-chloro-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
34	Chiral 	3-{4-[3-(3-Benzoyl-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
35	Chiral 	{4-[3-(3-Benzoyl-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
36	Chiral 	3-{4-[3-(5-Chloro-3-phenoxy-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid

No.	Structure	Name
37	 Chiral	3-{4-[3-(5-Chloro-3-phenoxy-pyridin-2-yloxy)-butoxy]-2-ethyl-phenyl}-propionic acid
38	 Chiral	{4-[3-(5-Chloro-3-phenoxy-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
39	 Chiral	3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid
40	 Chiral	3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid
41	 Chiral	3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid

No.	Structure	Name
42		3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-propoxy]-phenyl}-propionic acid (trifluoroacetic acid salt)
43		3-{4-[3-(5-Chloro-3-phenoxy-pyridin-2-yloxy)-propoxy]-2-methyl-phenyl}-propionic acid
44		3-{4-[2-(5-Chloro-3-phenoxy-pyridin-2-ylamino)-ethoxy]-2-methyl-phenyl}-propionic acid
45		3-{4-[3-(3-Benzoyl-5-ethyl-pyridin-2-yloxy)-propoxy]-2-methyl-phenyl}-propionic acid
46	Chiral 	3-{2-Methyl-4-[3-(6-methyl-2-phenoxy-pyridin-3-yloxy)-butoxy]-phenyl}-propionic acid

No.	Structure	Name
47		3-{4-[3-(5-Ethyl-biphenyl-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
48	Chiral 	3-{4-[3-(4-Ethyl-2-oxazol-2-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
49	Chiral 	3-{4-[3-(4-Ethyl-2-thiazol-4-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
50	Chiral 	3-{4-[3-(4-Ethyl-2-pyridin-2-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
51	Chiral 	{4-[3-(4-Ethyl-2-pyridin-2-yl-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
52	Chiral 	3-{2-Ethyl-4-[3-(4-ethyl-2-pyridin-2-yl-phenoxy)-butoxy]-phenyl}-propionic acid

No.	Structure	Name
53	Chiral 	3-{4-[3-(4-Chloro-2-pyridin-2-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
54	Chiral 	3-{2-Methyl-4-[3-(2-pyridin-2-yl-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid
55	Chiral 	3-{2-Ethyl-4-[3-(2-pyridin-2-yl-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid
56	Chiral 	3-{4-[3-(4-Ethyl-2-pyridin-3-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
57	Chiral 	3-{4-[3-(4-Chloro-2-pyridin-3-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
58	Chiral 	3-{4-[3-(4-Ethyl-2-pyridin-4-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid

No.	Structure	Name
59	 Chiral	3-{2-Methyl-4-[3-(2-pyridin-4-yl-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid
60	 Chiral	3-{2-Ethyl-4-[3-(2-pyridin-4-yl-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid
61	 Chiral	3-{4-[3-(2-Benzo[d]isoxazol-3-yl-4-chloro-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
62		3-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
63		{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenoxy}-acetic acid
64		{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid

No.	Structure	Name
65		{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
66		{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butylsulfanyl]-2-methyl-phenoxy}-acetic acid
67		3-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butylsulfanyl]-2-methyl-phenyl}-propionic acid
68		2-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenoxy}-2-methyl-propionic acid
69		{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-phenoxy}-acetic acid

No.	Structure	Name
70		3-{4-[3-(2-Benzoyl-4-isopropyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
71	Chiral 	3-{4-[3-(2-Benzoyl-4-cyclopropyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
72		3-{4-[3-(2-Benzoyl-4-trifluoromethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
73		3-{4-[3-(2-Benzoyl-4-chloro-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
74		3-{4-[3-(2-Benzoyl-4-chloro-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid

No.	Structure	Name
75	Chiral 	3-{4-[3-(2-Benzoyl-4-methoxy-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
76	Chiral 	3-{4-[3-(2-Benzoyl-4-fluoro-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
77	Chiral 	3-{4-[3-(2-Benzoyl-4-isopropyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
78	Chir 	{4-[3-(2-Benzoyl-4-isopropyl-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
79		{4-[3-(2-Benzoyl-4-chloro-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid

No.	Structure	Name
80		3-(4-{3-[4-Ethyl-2-(hydroxy-phenyl-methyl)-phenoxy]-butoxy}-2-methyl-phenyl)-propionic acid
81		3-(4-{3-[4-Ethyl-2-(hydroxyimino-phenyl-methyl)-phenoxy]-butoxy}-2-methyl-phenyl)-propionic acid
82		3-(4-{3-[4-Ethyl-2-(methoxyimino-phenyl-methyl)-phenoxy]-butoxy}-2-methyl-phenyl)-propionic acid
83	 Chiral	3-{4-[3-(4-Isopropyl-2-phenoxy-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
84	 Chiral	{4-[3-(4-Isopropyl-2-phenoxy-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid

No.	Structure	Name
85		3-{4-[3-(4-Ethyl-2-isobutyryl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
86		3-{4-[3-(2-Cyclopropanecarbonyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
87		3-{4-[3-(2-Cyclopropanecarbonyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
88		3-{4-[3-(2-Cyclopentanecarbonyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
89		2-{4-[3-(4-Ethyl-2-isobutyryl-phenoxy)-butoxy]-phenoxy}-2-methyl-propionic acid
90		2-{4-[3-(2-Cyclopropanecarbonyl-4-ethyl-phenoxy)-butoxy]-phenoxy}-2-methyl-propionic acid

No.	Structure	Name
91		3-{4-[3-(3-Benzoyl-5-ethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
92		{4-[3-(3-Benzoyl-5-ethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
93	Chiral 	3-{4-[3-(3-Benzoyl-5-chloro-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
94	Chiral 	{4-[3-(3-Benzoyl-5-chloro-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
95	Chiral 	3-{4-[3-(3-Benzoyl-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid

No.	Structure	Name
96	Chiral 	{4-[3-(3-Benzoyl-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
97	Chiral 	3-{4-[3-(5-Chloro-3-phenoxy-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
98	Chiral 	3-{4-[3-(5-Chloro-3-phenoxy-pyridin-2-yloxy)-butoxy]-2-ethyl-phenyl}-propionic acid
99	Chiral 	{4-[3-(5-Chloro-3-phenoxy-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
100	Chiral 	3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid

No.	Structure	Name
101	 Chiral	3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid
102	 Chiral	3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid
103		3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-propoxy]-phenyl}-propionic acid (trifluoroacetic acid salt)
104		3-{4-[3-(5-Chloro-3-phenoxy-pyridin-2-yloxy)-propoxy]-2-methyl-phenyl}-propionic acid
105		3-{4-[2-(5-Chloro-3-phenoxy-pyridin-2-ylamino)-ethoxy]-2-methyl-phenyl}-propionic acid

No.	Structure	Name
106		3-{4-[3-(3-Benzoyl-5-ethyl-pyridin-2-yloxy)-propoxy]-2-methyl-phenyl}-propionic acid
107	Chiral 	3-{2-Methyl-4-[3-(6-methyl-2-phenoxy-pyridin-3-yloxy)-butoxy]-phenyl}-propionic acid
108		3-{4-[3-(5-Ethyl-biphenyl-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
109	Chiral 	3-{4-[3-(4-Ethyl-2-oxazol-2-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
110	Chiral 	3-{4-[3-(4-Ethyl-2-thiazol-4-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
111	Chiral 	3-{4-[3-(4-Ethyl-2-pyridin-2-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid

No.	Structure	Name
112	Chiral 	{4-[3-(4-Ethyl-2-pyridin-2-yl-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
113	Chiral 	3-{2-Ethyl-4-[3-(4-ethyl-2-pyridin-2-yl-phenoxy)-butoxy]-phenyl}-propionic acid
114	Chiral 	3-{4-[3-(4-Chloro-2-pyridin-2-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
115	Chiral 	3-{2-Methyl-4-[3-(2-pyridin-2-yl-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid
116	Chiral 	3-{2-Ethyl-4-[3-(2-pyridin-2-yl-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid
117	Chiral 	3-{4-[3-(4-Ethyl-2-pyridin-3-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid

No.	Structure	Name
118	 Chiral	3-{4-[3-(4-Chloro-2-pyridin-3-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
119	 Chiral	3-{4-[3-(4-Ethyl-2-pyridin-4-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
120	 Chiral	3-{2-Methyl-4-[3-(2-pyridin-4-yl-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid
121	 Chiral	3-{2-Ethyl-4-[3-(2-pyridin-4-yl-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid
122	 Chiral	3-{4-[3-(2-Benzo[d]isoxazol-3-yl-4-chloro-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
123	 Chiral	(R)-{4-[3-(4-ethyl-2-phenoxy-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid

No.	Structure	Name
124	Chiral 	(R)-{4-[3-(2-benzoyl-4-methyl-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
125	Chiral 	(R)-{4-[3-(2-benzoyl-4-trifluoromethoxy-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
126		{4-[3-(2-benzoyl-4-ethyl-phenoxy)-hexyloxy]-2-methyl-phenylsulfanyl}-acetic acid
127		3-{4-[3-(2-benzoyl-4-ethyl-phenoxy)-hexyloxy]-2-methyl-phenyl}-propionic acid
128	Chiral 	(R)-3-{4-[3-(4-ethyl-2-phenoxy-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid

No.	Structure	Name
129	Chiral 	(R)-3-(4-{3-[4-ethyl-2-(1-phenyl-vinyl)-phenoxy]-butoxy}-2-methyl-phenyl)-propionic acid
130	Chiral 	(R)-3-(4-{3-[4-ethyl-2-(1-methyl-1-phenyl-ethyl)-phenoxy]-butoxy}-2-methyl-phenyl)-propionic acid
131	Chiral 	(R)-3-{4-[3-(2-benzoyl-4-methyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
132	Chiral 	(R)-3-(4-{3-[4-ethyl-2-(1-phenyl-ethyl)-phenoxy]-butoxy}-2-methyl-phenyl)-propionic acid
133	Chiral 	(R)-3-(4-{3-[4-ethyl-2-(pyridine-2-carbonyl)-phenoxy]-butoxy}-2-methyl-phenyl)-propionic acid

No.	Structure	Name
134		3-(2-methyl-4-{3-[2-(thiophene-2-carbonyl)-4-trifluoromethoxy-phenoxy]-butoxy}-phenyl)-propionic acid
135		3-(4-{3-[4-ethyl-2-(thiophene-2-carbonyl)-phenoxy]-butoxy}-2-methyl-phenyl)-propionic acid
136		3-(4-{3-[4-ethyl-2-(naphthalene-1-carbonyl)-phenoxy]-butoxy}-2-methyl-phenyl)-propionic acid
137		3-(4-{3-[4-ethyl-2-(1-phenyl-vinyl)-phenoxy]-butoxy}-2-methyl-phenyl)-propionic acid
138		3-{4-[3-(2-benzoyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid

No.	Structure	Name
139		3-{4-[3-(2-benzoyl-4-methyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
140		3-{4-[3-(2-benzyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
141		3-{4-[3-(2-benzoyl-4-bromo-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
142		3-{4-[3-(2-benzoyl-4-butyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
143		3-{4-[3-(2-benzoyl-4-propyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid

No.	Structure	Name
144		3-{4-[4-(2-benzoyl-4-ethyl-phenoxy)-1-methyl-butoxy]-2-methyl-phenyl}-propionic acid
145		3-{4-[4-(2-benzoyl-4-ethyl-phenoxy)-pentyloxy]-2-methyl-phenyl}-propionic acid
146		3-{4-[3-(2-benzoyl-4-ethyl-phenoxy)-2-methyl-propoxy]-2-methyl-phenyl}-propionic acid
147		3-{4-[3-(2-benzoyl-4-ethyl-phenoxy)-propoxy]-2-methyl-phenyl}-propionic acid
148		3-(4-{3-[4-ethyl-2-(4-fluoro-benzoyl)-phenoxy]-propoxy}-2-methyl-phenyl)-propionic acid

No.	Structure	Name
149		3-(4-{3-[4-ethyl-2-(2-trifluoromethyl-benzoyl)-phenoxy]-propoxy}-2-methyl-phenyl)-propionic acid
150		3-(4-{3-[4-ethyl-2-(3-trifluoromethyl-benzoyl)-phenoxy]-propoxy}-2-methyl-phenyl)-propionic acid
151		3-(4-{3-[4-ethyl-2-(thiophene-2-carbonyl)-phenoxy]-propoxy}-2-methyl-phenyl)-propionic acid
152		3-{4-[3-(2-benzyl-4-ethyl-phenoxy)-propoxy]-2-methyl-phenyl}-propionic acid
153		3-(4-{3-[4-ethyl-2-(naphthalene-1-carbonyl)-phenoxy]-propoxy}-2-methyl-phenyl)-propionic acid

No.	Structure	Name
154		3-(4-{3-[4-ethyl-2-(1-phenyl-vinyl)-phenoxy]-propoxy}-2-methyl-phenyl)-propionic acid
155		2-{4-[3-(2-benzoyl-4-ethyl-phenoxy)-butoxy]-phenoxy}-2-methyl-propionic acid
156		2-{4-[3-(2-benzoyl-4-ethyl-phenoxy)-2-methyl-propoxy]-phenoxy}-2-methyl-propionic acid
157		2-{4-[3-(2-benzyl-4-ethyl-phenoxy)-butoxy]-phenoxy}-2-methyl-propionic acid

No.	Structure	Name
158		2-{4-[3-(2-benzoyl-4-bromo-phenoxy)-butoxy]-phenoxy}-2-methyl-propionic acid
159		2-{4-[3-(2-benzoyl-4-butyl-phenoxy)-butoxy]-phenoxy}-2-methyl-propionic acid
160	 Chiral	(R)- 3-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
161	 Chiral	(R)-3-{2-methyl-4-[3-(2-phenoxy-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid
162	 Chiral	(R)-3-{2-methyl-4-[3-(2-phenoxy-4-trifluoromethoxy-phenoxy)-butoxy]-phenyl}-propionic acid

No.	Structure	Name
163	 Chiral	(R)-3-{2-methyl-4-[3-(4-methyl-2-phenoxy-phenoxy)-butoxy]-phenyl}-propionic acid
164	 Chiral	(R)-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
165		3-{4-[3-(4-chloro-2-phenoxy-phenoxy)-propoxy]-2-methyl-phenyl}-propionic acid
166	 Chiral	(R)-3-{4-[3-(2-benzo[b]thiophen-3-yl-4-chloro-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
167	 Chiral	(R)- 3-{4-[3-(4-chloro-2-pyridin-3-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
168	 Chiral	(R)-3-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-phenyl}-2,2-difluoro-propionic acid

No.	Structure	Name
169	Chiral 	%)(R)-3-{3-bromo-4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-phenyl}-propionic acid
170	Chiral 	(R)-3-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-3-methyl-phenyl}-propionic acid
171	Chiral 	(R)-{3-bromo-4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-phenyl}-acetic acid
172	Chiral 	(R)-3-{4-[3-(4-bromo-2-trifluoromethoxy-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
173	Chiral 	(R)-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-3-methyl-phenyl}-acetic acid

No.	Structure	Name
174	 Chiral	(R)-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-phenyl}-acetic acid
175	 Chiral	(R)-3-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-2-trifluoromethyl-phenyl}-propionic acid
176	 Chiral	(R)-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butylsulfanyl]-2-methyl-phenoxy}-acetic acid
177	 Chiral	(R)-3-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butylsulfanyl]-2-methyl-phenyl}-propionic acid
178	 Chiral	(R)-3-{2-Chloro-4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-phenyl}-propionic acid

No.	Structure	Name
179	 Chiral	(R)-3-{4-[3-(4-Chloro-2-phenoxy-phenoxy)-butoxy]-2-fluoro-phenyl}-propionic acid
180	 Chiral	(R)-3-{4-[3-(4-Chloro-2-phenoxy-phenoxy)-butoxy]-2-ethyl-phenyl}-propionic acid
181	 Chiral	(R)-3-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-chloro-phenyl}-propionic acid
182	 Chiral	(R)-3-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-fluoro-phenyl}-propionic acid
183	 Chiral	(R)-3-{4-[3-(4-Chloro-2-phenoxy-phenoxy)-butoxy]-phenyl}-propionic acid
184	 Chiral	(R)-3-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-phenyl}-propionic acid

No.	Structure	Name
185	 Chiral Isomer 1	(R)-3-{4-[3-(4-Chloro-2-phenoxy-phenoxy)-pentyloxy]-2-methyl-phenyl}-propionic acid
186	 Chiral Isomer 1	(R)-3-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-pentyloxy]-2-methyl-phenyl}-propionic acid
187	 Chiral	(R)-{4-[3-(3-Benzoyl-naphthalen-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
188	 Chiral	(R)-3-{4-[3-(3-Benzoyl-naphthalen-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
189	 Chiral	(R)-3-{4-[3-(4-Ethyl-2-phenoxy-phenoxy)-butylsulfanyl]-2-methyl-phenyl}-propionic acid
190	 Chiral	(R)-3-{4-[3-(4-Isopropyl-2-phenoxy-phenoxy)-butylsulfanyl]-2-methyl-phenyl}-propionic acid

No.	Structure	Name
191	 Chiral	(R)-3-{4-[3-(4-Chloro-2-phenoxy-phenoxy)-butoxy]-2-propyl-phenyl}-propionic acid
192	 Chiral	(R)-{4-[3-(4-Chloro-2-phenoxy-phenoxy)-butoxy]-2-ethyl-phenylsulfanyl}-acetic acid
193	 Chiral	(R)-3-{4-[3-(2-Benzoyl-4,5-dichloro-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
194	 Chiral	(R)-3-{2-Methyl-4-[3-(2-phenoxy-4-trifluoromethyl-phenoxy)-butylsulfanyl]-phenyl}-propionic acid
195	 Chiral	(R)-3-{2-Ethyl-4-[3-(4-ethyl-2-phenoxy-phenoxy)-butoxy]-phenyl}-propionic acid
196	 Chiral	(R)-3-{2-Ethyl-4-[3-(2-phenoxy-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid

No.	Structure	Name
197	 Chiral	(R)-3-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-ethyl-phenyl}-propionic acid
198	 Chiral	(R)-3-{2-Ethyl-4-[1-methyl-3-(2-phenoxy-4-trifluoromethyl-phenoxy)-propoxy]-phenyl}-propionic acid
199	 Chiral	(R)-3-{2-Methyl-4-[1-methyl-3-(2-phenoxy-4-trifluoromethoxy-phenoxy)-propylsulfanyl]-phenyl}-propionic acid
200	 Chiral	(S)-3-{4-[3-(4-Chloro-2-phenoxy-phenoxy)-butoxy]-2-ethyl-phenyl}-propionic acid
201		3-{4-[3-(4-Chloro-2-phenoxy-phenoxy)-propoxy]-2-ethyl-phenyl}-propionic acid
202	 Chiral	(R)-3-{4-[3-(2,4-Diphenoxy-phenoxy)-butoxy]-2-ethyl-phenyl}-propionic acid

No.	Structure	Name
203		2-{4-[4-(4-Chloro-2-phenoxy-phenyl)-3-methyl-butoxy]-2-methyl-phenyl}-cyclopropanecarboxylic acid
204		(R, S)-2-{4-[3-(4-Ethyl-2-phenylsulfanyl-phenoxy)-butoxy]-phenoxy}-2-methyl-propionic acid
205		2-{4-[3-(R,S-2-Benzenesulfinyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-2-methyl-propionic acid (enamtiomer pair 1)
206		(R, S)-2-{4-[3-(2-Cyclopropylmethyl-4-trifluoromethyl-phenoxy)-butoxy]-phenoxy}-2-methyl-propionic acid
207		(R, S)-2-Methyl-2-{4-[3-(2-methyl-3-phenyl-7-propyl-benzofuran-6-yloxy)-butoxy]-phenoxy}-propionic acid

No.	Structure	Name
208		(R, S)-2-Methyl-2-{4-[3-(4-methyl-3-phenyl-7-propyl-benzofuran-6-yloxy)-butoxy]-phenoxy}-propionic acid
209		(R, S)-2-{4-[3-(2-Cyclopropylmethyl-4-trifluoromethyl-phenoxy)-butoxy]-2-methyl-phenoxy}-2-methyl-propionic acid
210		(R, S)-3-{4-[3-(2-Cyclopropylmethyl-4-trifluoromethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
211	Chiral 	3-{R-4-[3-(R, S-2-Benzenesulfinyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
212		3-{4-[3-(4-Ethyl-2-phenylsulfanyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid isomer 2
213		(R, S)-2-{4-[3-(4-Ethyl-2-phenylsulfanyl-phenoxy)-butoxy]-phenoxy}-2-methyl-propionic acid

No.	Structure	Name
214		(R, S)-3-{4-[3-(R, S-2-Benzenesulfinyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
215		(R, S)-2-{4-[3-(R, S-2-Benzenesulfinyl-4-ethyl-phenoxy) -butoxy]-2-methyl-phenoxy}-2-methyl-propionic acid
216		(R, S)-3-{4-[3-(2-Benzenesulfonyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
217		3-{4-[3-(2-Benzoyl-4-trifluoromethoxy-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid

30. The compound of Claim 29, wherein the compound is



or a pharmaceutically acceptable salt, solvate or hydrate thereof.

31. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claims 1-30 or a pharmaceutically acceptable salt, solvate or hydrate thereof.

32. A pharmaceutical composition comprising:

(1) a compound of Claims 1-30, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof;

(2) a second therapeutic agent selected from the group consisting of: insulin sensitizers, sulfonylureas, biguanides, meglitinides, thiazolidinediones, α-glucosidase inhibitors, insulin secretogogues, insulin, antihyperlipidemic agents, plasma HDL-raising agents, HMG-CoA reductase inhibitors, statins, acryl CoA:cholestrol acyltransferase inhibitors, antiobesity compounds, antihypercholesterolemic agents, fibrates, vitamins and aspirin; and

(3) optionally a pharmaceutically acceptable carrier.

33. A method of modulating a peroxisome proliferator activated receptor (PPAR) comprising the step of contacting the receptor with a compound of Claims 1-30, or a pharmaceutically acceptable salt, solvate or hydrate thereof.

34. The method of Claim 33, wherein the PPAR is an alpha (α)-receptor.

35. The method of Claim 33, wherein the PPAR is a gamma (γ)-receptor.

36. The method of Claim 33, wherein the PPAR is a delta (δ)-receptor.

37. The method of Claim 33, wherein the PPAR is a gamma/delta (γ/δ)-receptor.

38. The method of Claim 33, wherein the PPAR is an alpha/gamma/delta ($\alpha/\gamma/\delta$)-receptor.

39. A method for treating or preventing a PPAR-γ mediated disease or condition in a mammal comprising the step of administering an effective amount of a compound of Claims 1-30.

40. A method for treating or preventing a PPAR-δ mediated disease or condition in a mammal comprising the step of administering an effective amount of a compound of Claims 1-30.

41. A method for treating or preventing a PPAR-γ/δ mediated disease or condition in a mammal comprising the step of administering an effective amount of a compound of Claims 1-30.

42. A method for treating or preventing a PPAR-$\alpha/\gamma/\delta$ mediated disease or condition in a mammal comprising the step of administering an effective amount of a compound of Claims 1-30.

43. A method for lowering blood-glucose in a mammal comprising the step of administering an effective amount of a compound of Claims 1-30.

44. A method of treating or preventing disease or condition in a mammal selected from the group consisting of hyperglycemia, dyslipidemia, Type II diabetes, Type I diabetes, hypertriglyceridemia, syndrome X, insulin resistance, heart failure, diabetic dyslipidemia, hyperlipidemia, hypercholesteremia, hypertension, obesity, anorexia bulimia, anorexia nervosa, cardiovascular disease and other diseases where insulin resistance is a component, comprising the step of administering an effective amount of a compound of Claims 1-30.

45. A method of treating or preventing diabetes mellitus in a mammal comprising the step of administering to a mammal a therapeutically effective amount of a compound of Claims 1-30.

46. A method of treating or preventing cardiovascular disease in a mammal comprising the step of administering to a mammal a therapeutically effective amount of a compound of Claims 1-30, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof.

47. A method of treating or preventing syndrome X in a mammal, comprising the step of administering to the mammal a therapeutically effective amount of a compound of Claims 1-30, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof.

48. A method of treating or preventing disease or condition in a mammal selected from the group consisting of hyperglycemia, dyslipidemia, Type II diabetes, Type I diabetes, hypertriglyceridemia, syndrome X, insulin resistance, heart failure, diabetic dyslipidemia, hyperlipidemia, hypercholesteremia, hypertension, obesity, anorexia bulimia, anorexia nervosa, cardiovascular disease and other diseases where insulin resistance is a component, comprising the step of administering an effective amount of a compound of Claims 1-30 and an effective amount of second therapeutic agent selected from the group consisting of: insulin sensitizers, sulfonylureas, biguanides, meglitinides, thiazolidinediones, α-glucosidase inhibitors, insulin secretogogues, insulin, antihyperlipidemic agents, plasma HDL-raising agents, HMG-CoA reductase inhibitors, statins, acryl CoA:cholestrol acyltransferase inhibitors, antiobesity compounds, antihypercholesterolemic agents, fibrates, vitamins and aspirin.

49. Use of a compound of Claims 1-30 and a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, for the manufacture of a medicament for the treatment of a condition modulated by a PPAR.